Biotech is going to have a hard time until the end of rate cycle, says E Squared's Les Funtleyder

Les Funtleyder, E Squared Capital Management portfolio manager, joins 'Power Lunch' to discuss his favorite stocks for Q4, how long it'll be until the small- and mid-cap biotech stocks move higher and more.